Phase III Trial of the Merck and NewLink Genetics Investigational Ebola Vaccine Initiated in Sierra Leone
17-Apr-2015 -
Merck, known as MSD outside the United States and Canada, and NewLink Genetics Corporation, confirmed that the third, late-stage, clinical trial of their Ebola vaccine candidate rVSV-ZEBOV-GP (V920) has been initiated in Sierra Leone. The vaccine candidate was originally developed by the Public ...
Ebola
MSD
phase II/III studies
+1